Myeloproliferative Neoplasms News

The Association of Community Cancer Centers’ Institute for Clinical Immuno-Oncology issued a white paper titled “Immuno-Oncology: There’s more to discover.”

The majority of U.S. hematologists–oncologists who use Twitter reported at least one financial conflict of interest made public through the federal Open Payments program, according to study results published in JAMA Internal Medicine.

Researchers have identified the chemical process behind the anticancer properties of piperlongumine, the compound found in the spicy Indian pepper plant.

Nearly one in five U.S. cancer survivors take medications for anxiety or depression, according to study results published in the Journal of Clinical Oncology.

The FDA granted orphan drug designation to BI 836858 for the treatment of myelodysplastic syndrome, according to the drug’s manufacturer.

Pediatric oncology patients with high degrees of symptom-related suffering appeared more likely than their parents to acknowledge the benefits of early palliative care, according to survey results.

Bruce E. Johnson, MD, FASCO, professor of medicine at Harvard Medical School and institute physician at Dana-Farber Cancer Institute, will become president of ASCO during the society’s annual meeting in June.

The FDA granted investigational new drug clearance for a phase 2 study of TZ 101-fucosylated hematopoietic stem cell transplants for children with hematologic malignancies, according to the agent’s manufacturer.

Exercise and psychological interventions provide greater benefit to patients than pharmaceutical drugs for reducing cancer-related fatigue, according to results of a meta-analysis.

This month’s top news includes a number of key studies in hematology and oncology.